{"filings":[{"id":99309,"accession_number":"0001193125-26-208966","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta Q1 GAAP EPS $2.88 vs loss of $4.60; siRNA pipeline shows early positive data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $330.5M (ELEVIDYS $102.0M, PMO $228.6M); total rev $730.8M (-2% YoY).","GAAP net income $331.0M vs loss of $447.5M; non-GAAP net income $385.4M.","siRNA candidates SRP-1001 (FSHD1) and SRP-1003 (DM1) show dose-dependent exposure and biomarker effects in Phase 1/2.","sNDA submitted to convert AMONDYS 45 and VYONDYS 53 to traditional approval; FY guidance reaffirmed $1.2-1.4B revenue.","ENDEAVOR Cohort 8 dosing underway for non-ambulatory DMD with sirolimus pretreatment; $40M milestone from Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":730803000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115230,"accession_number":"0001193125-26-072064","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sarepta CEO Douglas Ingram to retire by end of 2026; successor search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Douglas Ingram notified retirement by end of 2026 or upon appointment of replacement.","Board has commenced search for successor, considering internal and external candidates.","Ingram will remain CEO until successor is appointed or through 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115229,"accession_number":"0001193125-26-071566","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta reports Q4 2025 net loss of $412.2M; full-year revenue up 16% to $2.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net product revenue $1,864.3M (PMO $965.6M, ELEVIDYS $898.7M); Q4 net product revenue $369.6M.","GAAP net loss Q4 $412.2M ($3.93/share) vs Q4 2024 net income $159.0M; full-year GAAP net loss $713.4M.","Ended 2025 with ~$1.0B cash; refinanced $291.4M of 2027 notes to 2030 notes, removing near-term debt.","Japan launch of ELEVIDYS by Chugai in Feb 2026; eligible for $40M milestone. Positive 3-year EMBARK results.","Approval to begin Phase 1 trial of SRP-1005 (siRNA) for Huntington’s disease; Phase 1/2 SRP-1003 for DM1 advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":2198237000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115228,"accession_number":"0001193125-26-010116","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta preliminary 2025 net product revenue $1.86B; ELEVIDYS $898.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue Q4 $369.6M, full-year $1.86B; cash and investments $953.8M at year-end.","ELEVIDYS revenue Q4 $110.4M (impacted by flu and rescheduled infusions), full-year $898.7M.","PMO franchise revenue Q4 $259.2M, full-year $965.6M; described as durable.","CEO reconfirms ELEVIDYS annual sales floor of $500M; more detailed guidance deferred until initiatives evaluated.","Preliminary results unaudited; final Q4/FY 2025 results expected late February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":2198237000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131651,"accession_number":"0001193125-25-326969","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Sarepta exchanges $291.4M of 1.25% notes for 4.875% notes due 2030 plus $31.6M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged ~$291.4M of existing 1.25% Convertible Senior Notes due 2027 for new 4.875% Convertible Notes due 2030 plus ~$31.6M cash.","New notes issued as additional notes under August 2025 indenture; total 4.875% notes now ~$893.4M outstanding.","Exchange involved holders including entity affiliated with board member Michael Chambers.","Transaction closed December 18, 2025; extends maturity from 2027 to 2030 at higher coupon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131650,"accession_number":"0001193125-25-315032","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Sarepta exchanges $291M of 1.25% notes due 2027 for 4.875% notes due 2030 plus $31.6M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanges $291.4M principal of 1.25% convertibles due 2027 for same principal of 4.875% convertibles due 2030, plus $31.6M in cash.","New 4.875% notes are part of same series as $602M issued Aug 2025; post-exchange total $893.4M outstanding.","Approximately $158.6M of existing 1.25% notes will remain outstanding with unchanged terms.","Placement agent intends to buy ~691,000 SRPT shares in private transactions from exchanging investors at a discount.","Exchange expected to close on or about December 18, 2025, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131649,"accession_number":"0001193125-25-310588","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sarepta grants CEO Ingram $12M equity awards after 8-year gap","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Douglas Ingram granted ~$12M total equity: ~$6M time-based RSUs vesting over 3 years and ~$6M performance-based awards tied to Incentive EBITDA for 2026-2027.","Performance awards can pay out 0-200% of target; vesting subject to 3-year service period from Dec 7, 2025.","First equity grant for Ingram since 2017; previously deferred consistent with employment agreement.","Performance condition based on cumulative Incentive EBITDA over two-year period ending Dec 31, 2027.","Up to 269,542 shares at target across four award types (RSUs, units, restricted shares, performance shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131648,"accession_number":"0001193125-25-262591","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta reports Q3 GAAP net loss; ESSENCE confirmatory study misses primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ESSENCE study did not meet primary endpoint (p=0.309); COVID-adjusted analysis showed trend (p=0.09).","Net product revenue $370M (PMO $238.5M, ELEVIDYS $131.5M); total revenue $399.4M, down 15% YoY.","GAAP net loss $179.9M ($1.80 per share) vs net income $33.6M ($0.34) in Q3 2024.","Refinanced convertible debt to 2030; disposed Arrowhead equity; positive cash flow in Q3.","ELEVIDYS labeling discussions with FDA nearing conclusion; non-ambulatory indication removal expected."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1755303000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148217,"accession_number":"0001193125-25-192794","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Sarepta exchanges $700M convertible notes for $602M new 4.875% notes due 2030 plus stock and cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $700M of 1.25% Convertible Notes due 2027 for $602M of 4.875% Convertible Notes due 2030, 5.85M common shares, and ~$123.3M cash.","New notes mature Sept 1, 2030; initial conversion price ~$60.00/share (191.5% premium over $20.58 close on Aug 20, 2025).","Concurrent private placement of 1,106,806 shares to J. Wood Capital at $18.07 per share.","New notes bear 4.875% cash interest, payable semiannually; callable from Sept 6, 2028 if stock price ≥ 130% of conversion price.","Holders may convert upon stock price triggers (≥130% of conversion price for 20 of 30 days) or specified corporate events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148216,"accession_number":"0001193125-25-184625","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Sarepta exchanges $700M of 1.25% notes due 2027 for new 4.875% notes due 2030, stock, and cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged ~$700M existing 1.25% convertible notes for $602M new 4.875% notes due 2030, $110M stock, and ~$123.3M cash.","New notes conversion price ~$60/share, representing a 191.5% premium over the $20.58 Aug 20 closing price.","Private placement of $20M common stock to J. Wood Capital Advisors at price with floor of $14.41/share.","Up to 835,765 fee shares may be issued to J. Wood Capital Advisors for advisory services.","Exchange expected to close Aug 28, 2025, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148215,"accession_number":"0001193125-25-179819","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sarepta EVP Chief Technical Operations Officer Bilal Arif to depart Sept 16, 2025; severance $576,700","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bilal Arif's employment ends Sept 16, 2025; served as EVP, Chief Technical Operations Officer until Aug 12.","He will serve as Special Advisor to the President for the remainder of his employment.","Severance lump sum of $576,700 plus consulting fee of $400 per hour through Dec 31, 2025.","Outstanding equity awards continue to vest through employment and consulting period.","Departure part of strategic restructuring and pipeline prioritization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148214,"accession_number":"0001193125-25-161516","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA places clinical hold on Sarepta's LGMD gene therapy trials; revokes AAVrh74 platform designation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on LGMD trials for SRP-9003, SRP-9004, SRP-6004, and SRP-9005.","Sarepta had paused most LGMD programs on July 16, 2025; SRP-9003 was excepted.","FDA revoked AAVrh74 platform technology designation previously granted on June 2, 2025.","Sarepta plans to discuss accelerated approval pathway for SRP-9003 after clinical hold lifted.","Enrollment and dosing in Phase 3 trial SRP-9003-301 was completed in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148213,"accession_number":"0000950170-25-096257","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.","Preliminary Q2 2025 net product revenue $513M: ELEVIDYS $282M, PMOs $231M; cash & investments ~$850M.","FDA requested black box warning for acute liver injury/failure in ELEVIDYS label; Sarepta agrees, resolving material issues for ambulant patients.","Pipeline reprioritized to focus on siRNA platform; most LGMD gene therapies paused, except SRP-9003 BLA expected H2 2025.","Executive changes: Ian Estepan as President/COO, Louise Rodino-Klapac as President R&D, Ryan Wong as CFO; Dallan Murray departs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166984,"accession_number":"0000950170-25-083131","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sarepta shareholders approve 4.3M share increase to 2018 equity plan, 0.3M to ESPP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Vote approves adding 4,300,000 shares to 2018 Equity Incentive Plan (total now 17,487,596).","Vote approves adding 300,000 shares to 2016 ESPP (total now 1,700,000 shares).","Re-elected directors Barry, Behrens, Mayo, Nicaise with majority support.","Advisory vote on 2024 named executive officer compensation passed (72.1M for, 2.2M against).","Ratified KPMG as independent auditor for FY2025 (80.6M for, 3.9M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184369,"accession_number":"0000950170-25-027717","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS $384.2M; GAAP net income $159M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS contributed $384.2M; royalty from Roche $4.9M.","GAAP net income $159.0M ($1.50 diluted EPS); non-GAAP net income $206.0M ($1.90 EPS).","Full-year 2024 total revenues $1.9B (+53% YoY); GAAP net income $235.2M vs $536M net loss in 2023.","2025 net product revenue guidance $2.9B-$3.1B (70% YoY growth); ELEVIDYS expected to grow 162%.","Closed Arrowhead licensing deal for 4 clinical-stage siRNA programs; established $600M revolving credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1901979000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184368,"accession_number":"0001193125-25-026683","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Sarepta enters $600M senior secured revolving credit facility with JPMorgan as admin agent","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year $600M revolving credit facility closed Feb 13, 2025; variable interest at Adjusted SOFR + 1.125%-1.75% spread based on leverage.","Financial covenants: max secured net leverage ratio 3.5:1.0 (4.0:1.0 holiday for acquisitions); min interest coverage ratio 2.5:1.0.","Facility matures Feb 13, 2030; proceeds for general corporate purposes; secured by substantially all assets of obligors.","Commitment fee on unused portion ranges from 0.20% to 0.35% per annum based on total gross leverage ratio.","Lead arrangers include JPMorgan, Barclays, Citizens, Goldman Sachs, Morgan Stanley, and RBC as co-syndication agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184367,"accession_number":"0001193125-25-005160","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta reports preliminary Q4 2024 net product revenue $638.2M, FY2024 $1.79B, beating guidance by $100M+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary total net product revenue Q4 2024 $638.2M, FY2024 $1.79B, exceeding full-year guidance by over $100M.","ELEVIDYS net product revenue Q4 2024 $384.2M (up 112% sequential), FY2024 $820.8M.","RNA-based PMO net product revenue Q4 2024 $254.0M, FY2024 $967.2M, grew YoY.","Cash, cash equivalents, and investments ~$1.5B as of Dec 31, 2024.","Reiterated 2025 full-year net product revenue guidance of $2.9-3.1B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1901979000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200959,"accession_number":"0001193125-24-265627","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","5.02","8.01"],"status":"ready","headline":"Sarepta enters $500M upfront license deal with Arrowhead for siRNA therapies; GC resigns","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$500M upfront cash to Arrowhead; up to $300M near-term payments; up to $180M per program development milestones, $700M per program sales milestones; tiered royalties up to low double digits.","Sarepta purchases 11.9M shares of Arrowhead for $325M in a private placement, with 180-day lock-up and standstill for up to 5 years.","Programs include clinical siRNA candidates for FSHD, DM1, ataxias, IPF, and pre-clinical for Huntington's; Sarepta can select six additional discovery targets.","Arrowhead leads initial development and manufacturing; Sarepta assumes responsibility at transition points and holds global commercialization rights.","EVP Chief General Counsel Ryan Brown resigns effective Nov 26; Cristin Rothfuss named successor as EVP General Counsel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216974,"accession_number":"0000950170-24-106619","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Sarepta appoints Deirdre Connelly to board, increases board size to 9","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deirdre Connelly appointed as Class I director effective Sept. 12, 2024, term through 2026 annual meeting.","Initial equity grant of $712,500 in value, split equally between RSUs and stock options.","Equity vests in three equal annual installments starting Sept. 12, 2025; annual cash retainer $60,000.","Board amended bylaws to increase maximum director limit from 8 to 9, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236716,"accession_number":"0001193125-24-157458","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sarepta increases incentive plan shares by 500,000; all director nominees elected at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to 2024 Employment Commencement Incentive Plan, increasing share reserve by 500,000 to 6,185,308 shares.","At June 6 annual meeting, all four Class I director nominees (Douglas Ingram, Hans Wigzell, Kathryn Boor, Michael Chambers) were elected.","Advisory say-on-pay proposal passed with approximately 63.6 million votes for and 9.0 million against.","Stockholders ratified KPMG as independent auditor for 2024; approximately 77.1 million votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}